
|Articles|April 1, 2002
Protein may be treatment target in advanced PCa
Vancouver, British Columbia - Clusterin, a stress-related protein, appears to inhibit apoptosis associated with androgen withdrawal and may therefore be an important therapeutic target in men with advanced prostate cancer, say researchers from the University of British Columbia.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves first-line Zenflow system for the treatment of BPH
2
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC
5















